REGULATORY
Dr Nakashima of PMDA Proposes Freeze on NHI Prices of Generics for Which Companies Take Steps to Ensure Stable Supplies
Nobumasa Nakashima, director of the Pharmaceuticals and Medical Devices Agency’s (PMDA) Office of International Programs, proposed a plan to maintain the NHI prices of generic drugs for which manufacturers take necessary measures to ensure stable supplies at a general scientific…
To read the full story
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Health Minister Signals Early March Approval for iPSC Products
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





